

MARKET RELEASE

MedAdvisor completes shortfall share placement, signs 2 additional US health programs

Melbourne, Australia, 17 December, 2020 - Medtech company MedAdvisor Limited (ASX: MDR) today announces:

- The completion of its recent capital raising for a total of approximately AUD \$42.2 million including an additional ~\$4 million raised under the shortfall facility;
- A vaccine program signed up by Adheris for a 5-month period during FY21 for USD \$3.4 million (AUD \$4.7 million¹); and
- A USD \$1.3 million (AUD \$1.8 million) one-year deal signed with a top 10 global brand representing a ~30%+ increase on the FY20 deal.

Completion of Capital Raising

MedAdvisor has been successful in completing a placement of approximately \$4.0 million pursuant to the shortfall under the retail entitlement offer component of its recent capital raise for the acquisition of US-based Adheris from Syneos Health. 10,430,949 new shares will be issued to new institutional and sophisticated investors today at AUD \$0.38 per share.

No further shares will be issued under the shortfall capacity.

This shortfall placement follows strong support for the Entitlement Offer and institutional placement, which raised approximately AUD \$38.2 million (as announced on 12 November and 4 December). The Board is very pleased with the support shown by both existing and new shareholders through the capital raising, which has funded the upfront component of the acquisition of Adheris and provided additional working capital for MedAdvisor.

Vaccine program signed by Adheris

MedAdvisor is also pleased to announce that it has signed a vaccine for a 5-month program in FY21 via its Adheris subsidiary. The health program is with a top 10 global pharmaceutical company with a diversified portfolio and is a long-standing customer of both Adheris and MedAdvisor. Adheris has an existing Master Services Agreement (MSA) with the pharmaceutical company, however, this is a new Statement of Work relating to the FY21 year.

¹ AUD:USD assumed exchange rate of \$0.72

The 5-month program is contracted for USD \$3.4 million (AUD \$4.7 million). The program will leverage Adheris' analytics engine and network of 25k pharmacies with an opt-out population of approximately 180 million patients to deliver direct mail to appropriate patients at the right time. There are no conditions precedent and all material terms have been disclosed.

Commenting on the program, MedAdvisor US President, John Ciccio said: "We have developed ourselves as leaders in running health awareness campaigns and vaccination series completion campaigns to ensure that patients are fully vaccinated. Many vaccines require more than one dose to be effective. We have established a large network and range of tools that can help remind a patient to come back for a subsequent dose - something that is critical for the vaccine to be effective. In FY20 Adheris ran 7 vaccine programs all with similar objectives."

He continued: "Driving adherence is as important in vaccines as it is medication. Some of Adheris' biggest programs in recent years have been focused on vaccines for this reason. We believe there is a significant opportunity in the vaccines space for MedAdvisor in FY21 and beyond with increased global attention in this space following the developments with COVID-19 vaccines."

Continued growth in programs with existing clients

MedAdvisor has signed an additional one-year deal with a major global pharmaceutical company (market capitalisation in excess of USD \$140 billion). This particular program is worth AUD \$1.8 million and represents a 30% increase on Fy20's contract. This deal is consistent with MedAdvisor increasing its program sizes and developing deeper relationships with its global clients. This builds upon the recently announced AUD \$2.6m deal with another client that represented a 20% increase on the prior year's contracted value.

This document has been authorised for release by Robert Read, MedAdvisor CEO and Managing Director.

- ENDS -

For more information:

Simon Glover
Chief Financial Officer
corporate@medadvisor.com.au
+61 3 9095 3036

Alex Beashel
Corporate Communications
ab@alexbeashel.com
+61 466 308 667

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over 1.6 million users through more than 60% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has recently partnered with HMS in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors